QF
MRSN

QVT Financial’s Mersana Therapeutics MRSN Stock Holding History

QVT Financial’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,506
Closed -$18.5K – 60
2025
Q2 		$18.5K Hold
2,506
– – ﹤0.01% 46
2025
Q1 		$21.6K Hold
2,506
– – ﹤0.01% 40
2024
Q4 		$89.6K Hold
2,506
– – 0.01% 35
2024
Q3 		$118K Hold
2,506
– – 0.01% 35
2024
Q2 		$126K Hold
2,506
– – 0.01% 33
2024
Q1 		$283K Hold
2,506
– – 0.02% 35
2023
Q4 		$145K Hold
2,506
– – 0.01% 34
2023
Q3 		$79.6K Hold
2,506
– – ﹤0.01% 39
2023
Q2 		$206K Hold
2,506
– – 0.01% 43
2023
Q1 		$258K Hold
2,506
– – 0.01% 51
2022
Q4 		$367K Hold
2,506
– – 0.02% 48
2022
Q3 		$424K Hold
2,506
– – 0.03% 51
2022
Q2 		$289K Hold
2,506
– – 0.02% 60
2022
Q1 		$250K Hold
2,506
– – 0.01% 67
2021
Q4 		$390K Hold
2,506
– – 0.01% 58
2021
Q3 		$591K Hold
2,506
– – 0.04% 58
2021
Q2 		$851K Hold
2,506
– – 0.06% 51
2021
Q1 		$1.01M Buy
+2,506
New +$1.22M 0.07% 47

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial's MRSN Position: Q3 2025 in Review

QVT Financial sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 2,506 shares — an estimated $18.5K sold.

QVT Financial first reported a position in MRSN in Q1 2021 and held it in 18 quarters. The position peaked at $1.01M in Q1 2021. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • QVT Financial reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • QVT Financial sold 2,506 Mersana Therapeutics shares in Q3 2025, an estimated $18.5K.
  • QVT Financial first reported a position in Mersana Therapeutics in Q1 2021 and held it in 18 quarters.
  • QVT Financial's Mersana Therapeutics position peaked at $1.01M in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on QVT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.